{"nctId":"NCT00761319","briefTitle":"Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","startDateStruct":{"date":"2008-10"},"conditions":["Open-angle Glaucoma","Ocular Hypertension"],"count":705,"armGroups":[{"label":"Travoprost","type":"EXPERIMENTAL","interventionNames":["Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)"]},{"label":"Latanoprost","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)"]}],"interventions":[{"name":"Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)","otherNames":["TRAVATAN Z®"]},{"name":"Latanoprost ophthalmic solution 0.005% (XALATAN®)","otherNames":["XALATAN®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years or older.\n* Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as specified in protocol.\n* Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.\n* Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least one continuous month prior to Visit 1.\n* Willing and able to discontinue use of any topical ocular medicine other than the study medication for the duration of the study, including artificial tears.\n* Best corrected visual acuity of -0.6 logMAR or better in each eye.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article.\n* Use of contact lenses within 30 days of Visit 1.\n* Use of contact lenses during the study.\n* Participation in an investigational drug or device study within 30 days of entering this study.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score","description":"The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. A negative number represents a perceived improvement in ocular health.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"1.0"},{"groupId":"OG001","value":"-10.2","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Corneal Fluorescein Staining Score = 0","description":"The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (\\>50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by tht total number of patients analyzed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":353},"commonTop":[]}}}